Research ArticleNEUROPHARMACOLOGY

Enhanced Anticonvulsant Activity of Ganaxolone after Neurosteroid Withdrawal in a Rat Model of Catamenial Epilepsy

Doodipala S. Reddy and Michael A. Rogawski
Journal of Pharmacology and Experimental Therapeutics September 2000, 294 (3) 909-915;

Abstract

Perimenstrual catamenial epilepsy, the exacerbation of seizures in association with menstruation, may in part be due to withdrawal of the progesterone metabolite allopregnanolone (3α-hydroxy-5α-pregnan-20-one), an endogenous anticonvulsant neurosteroid that is a positive allosteric modulator of γ-aminobutyric acidA receptors. Neurosteroid replacement is a potential approach to therapy, but natural neurosteroids have poor bioavailability and may be converted to metabolites with undesired progestational activity. The synthetic neuroactive steroid ganaxolone (3α-hydroxy-3β-methyl-5α-pregnane-20-one) is an orally active analog of allopregnanolone that is not converted to the hormonally active 3-keto form. To assess the potential of ganaxolone in the treatment of catamenial seizure exacerbations, a state of persistently high serum progesterone (pseudopregnancy) was induced in 26-day-old female rats with gonadotropins, and neurosteroids were withdrawn on postnatal day 39 with finasteride, a 5α-reductase inhibitor that blocks the conversion of progesterone to allopregnanolone. Finasteride treatment during pseudopregnancy results in a reduction in the threshold for pentylenetetrazol seizures. During this state of enhanced seizure susceptibility, there was a 3-fold increase in the anticonvulsant potency of ganaxolone (control ED50 = 3.5 mg/kg; withdrawn = 1.2 mg/kg) without a change in the potency for induction of motor toxicity in the rotarod test. The plasma concentrations of ganaxolone did not differ significantly in control and withdrawn animals; the estimated plasma concentrations of ganaxolone producing 50% seizure protection were ∼500 and ∼225 ng/ml in control and withdrawn rats, respectively. Unlike ganaxolone, neurosteroid withdrawal was associated with a decrease in the anticonvulsant potency of diazepam (control ED50 = 1.9 mg/kg; withdrawn = 4.1 mg/kg) and valproate (control ED50 = 279 mg/kg; withdrawn = 460 mg/kg). The enhanced anticonvulsant potency of ganaxolone after neurosteroid withdrawal supports the use of ganaxolone as a specific treatment for perimenstrual catamenial epilepsy.

Catamenial epilepsy, the recurrent exacerbation of seizures at specific times during the menstrual cycle, affects from 10 to 72% of women with epilepsy (Ansell and Clarke, 1956; Laidlaw, 1956; Rosciszewska, 1986; Tauboll et al., 1991; Duncan et al., 1993). In many women with catamenial epilepsy, catamenial seizure clustering occurs just before or during menstruation, in association with a fall in serum progesterone levels (Newmark and Penry, 1980; Herzog et al., 1997). Progesterone has anticonvulsant properties in large part due to its conversion to the neuroactive steroid allopregnanolone, a potent positive modulator of γ-aminobutyric acid (GABAA) receptors (Laidlaw, 1956; Kokate et al., 1994, 1999). Thus, perimenstrual seizure exacerbations in women with catamenial epilepsy could be related to neurosteroid withdrawal. Although natural progesterone therapy benefits some women with catamenial epilepsy (Herzog, 1986, 1995), it may be associated with undesired hormonal side effects. GABAAreceptor-modulating neurosteroids, which are devoid of such hormonal actions, may provide a rational alternative approach to therapy (Reddy and Kulkarni, 2000). However, certain obstacles prevent the clinical use of endogenously occurring neurosteroids. Importantly, natural neurosteroids such as allopregnanolone have low bioavailability because they are rapidly inactivated and eliminated by glucuronide or sulfate conjugation at the 3α-hydroxyl group. In addition, the 3α-hydroxyl group of allopregnanolone may undergo oxidation to the ketone, restoring activity at steroid hormone receptors (Rupprecht et al., 1993). Ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnane-20-one), the synthetic 3β-methyl analog of allopregnanolone, overcomes these limitations (Carter et al., 1997). Like allopregnanolone, ganaxolone is a positive allosteric modulator of GABAA receptors and is an effective anticonvulsant in the pentylenetetrazol (PTZ) seizure test as well as in other anticonvulsant screening models (Carter et al., 1997;Gasior et al., 1997). However, ganaxolone is orally active, and adequate blood levels can be maintained in human subjects with two or three times daily dosing (Monaghan et al., 1997). In addition, although ganaxolone is extensively metabolized, the potentially hormonally active 3-keto derivative is not formed.

To evaluate the potential of ganaxolone in the treatment of perimenstrual seizure exacerbations, we developed a rat model of catamenial epilepsy in which female pseudopregnant rats were abruptly withdrawn from neurosteroids to simulate the drop occurring in women before the menses. Pseudopregnancy, a state in which progesterone and allopregnanolone are chronically elevated, was produced by gonadotropin treatment. Neurosteroid withdrawal was induced by the administration of finasteride, a 5α-reductase inhibitor that blocks the conversion of progesterone to allopregnanolone (Azzolina et al., 1997). After neurosteroid withdrawal, animals exhibit a marked enhancement in seizure susceptibility when challenged with PTZ. Unexpectedly, we found that the anticonvulsant potency of ganaxolone was enhanced in the period after neurosteroid withdrawal, whereas the potencies of two reference anticonvulsants diazepam and valproate were reduced.

Materials and Methods

Animals.

Female 26-day-old (70–80 g) and 40- to 45-day-old (200–250 g) Sprague-Dawley rats (Taconic) were housed in groups of four under a 12-h light/dark cycle in an environmentally controlled animal facility. Animals were allowed to acclimatize with free access to food and water for a 24-h period before use. All procedures were performed in strict compliance with the National Institutes of HealthGuide for the Care and Use of Laboratory Animals under a protocol approved by the National Institutes of Health Animal Use Committee.

Pseudopregnancy Model of Catamenial Epilepsy.

Rats were injected with pregnant mare serum gonadotropin (20 IU/rat s.c.) at 10:00 AM on postnatal day 27 followed 48 h later by human chorionic gonadotropin (10 IU/rat s.c.). The day of human chorionic gonadotropin treatment (day 29) was considered day 0 of pseudopregnancy. At 11:00 AM on day 11 of pseudopregnancy, neurosteroid withdrawal was induced with finasteride (100 mg/kg in 50% β-cyclodextrin i.p.), which blocks the conversion of progesterone to allopregnanolone via inhibition of 5α-reductase isoenzymes (Kokate et al., 1999). In some experiments, animals were injected with vehicle alone. At 24 h after finasteride treatment, plasma allopregnanolone levels were reduced from 44.5 to 6.4 ng/ml; there was no effect on serum progesterone levels (D. S. Reddy, H.-Y. Kim, and M. A. Rogawski, unpublished observations).

PTZ Seizure Test.

Protective activity against PTZ-induced clonic seizures was evaluated according to the procedure described byWhite et al. (1995). Testing was carried out on day 12 of pseudopregnancy (24 h after vehicle or finasteride administration) for pseudopregnant control or pseudopregnant withdrawn animals or in naive cycling (nonpseudopregnant) control animals. Rats were injected s.c. with ganaxolone or i.p. with diazepam and valproate and 15 min (ganaxolone) or 30 min (diazepam and valproate) later received an s.c. injection of PTZ at a dose of 90 mg/kg. The pretreatment times were based on the time to peak effect (White et al., 1995; see Carter et al., 1997). The 50% convulsant dose (CD50) for PTZ is 60 mg/kg in naive (diestrous) female rats, 73 mg/kg in pseudopregnant animals, and 46 mg/kg in pseudopregnant withdrawn (D. S. Reddy, H.-Y. Kim, and M. A. Rogawski, unpublished observations). With the dose of PTZ used in this study, all animals in each of the three groups experienced seizures in the absence of anticonvulsant pretreatment. Animals were observed for a 30-min period after PTZ administration. Rats failing to show clonic spasms lasting longer than 5 s were scored as protected.

Rotarod Motor Toxicity Test.

Ganaxolone and other test drugs were evaluated for motor toxicity in an accelerating rotarod test (initial speed 5 rpm, increasing 5 rpm/30 s; Jones and Roberts, 1968). Rats were acclimatized to the rotarod (Ugo Basile, Milan, Italy) 30 min before the start of the experiment. Rats that successfully remained on the rotarod for more than 2 min were selected for drug testing. After administration of the test drug, rats were given three successive opportunities to remain on the rotarod continuously for 2 min. An animal was considered to have motor toxicity if it fell from the rotarod more than twice in the 2-min period.

Ganaxolone Plasma Level Determinations.

Animals were anesthetized with CO2 gas, and ∼2 ml carotid blood was collected in heparinized tubes. The plasma was separated by centrifugation at 12,000g for 10 min and stored at −20°C in 10-ml glass tubes containing 7.5% EDTA solution (68 μl). The concentration of ganaxolone was analyzed by liquid chromatography-mass spectroscopy using a Hewlett-Packard liquid chromatograph (analytical column: Genesis C18, 4 μm, 3 × 30 mm, Jones Chromatography) and Micromass Quattro II mass spectrometer. Briefly, a 0.2-ml plasma sample was added to a tube containing evaporated internal standard (epiallopregnanolone). The steroid and internal standard were extracted with 4 ml of hexane. Each sample was analyzed using the atmospheric pressure chemical ionization technique under acidic conditions. A standard curve was plotted using pure ganaxolone in methanol mixed with 0.2 ml of blank rat plasma.

Drugs and Hormones.

Pregnant mare serum gonadotropin and human chorionic gonadotropin were administered in sterile saline. Finasteride and ganaxolone were made fresh each day in aqueous 50% 2-hydroxypropyl-β-cyclodextrin (β-cyclodextrin; Research Biochemicals International, Natick, MA). By itself, β-cyclodextrin at concentrations as high as 50% failed to affect PTZ seizures. Diazepam and sodium valproate were dissolved in sterile isotonic saline. The diazepam solution contained a maximum of 20% propylene glycol and 5% ethyl alcohol. Drug solutions were administered s.c. or i.p. in a volume equaling 1% of the animal's body weight. Ganaxolone was a gift of CoCensys (Irvine, CA). Epiallopregnanolone (3β-hydroxy-5α-pregnan-20-one) was obtained from Steraloids (Newport, RI). Diazepam injection was obtained from Elkins-Sinn (Cherry Hill, NJ). All other drugs and hormones were obtained from Sigma Chemical Co. (St. Louis, MO).

Data Analysis.

To construct dose-effect curves, drugs were tested at several doses spanning the dose producing seizures in 50% of animals (CD50), or resulting in 50% seizure protection (ED50) or motor toxicity (TD50). Each group consisted of six to eight rats. CD50, ED50, and TD50 values with 95% confidence limits (CL) were determined by log-probit analysis using the Litchfield and Wilcoxon procedure (PHARM/PCS Version 4.2; Microcomputer Specialists, Philadelphia, PA). Dose-response data were fit to the logistic function 100/[1 + (D50/x)nH] where x is the dose administered; D50is either the CD50, ED50 or TD50; and nH is an empirical parameter describing the steepness of fit. When appropriate, the nH values were determined simultaneously using ALLFIT 2.7 (abs.cit.nih.gov/dload/allfit/; DeLean et al., 1978). The significance of differences between the dose-response curves was determined using the Litchfield-Wilcoxon χ2 test, where the criterion for statistical significance was P < .05. Protective index, a quantitative measure of the margin between doses producing anticonvulsant protection and motor toxicity, was calculated by dividing the TD50 value by the ED50 value. Statistical differences among mean plasma ganaxolone levels were analyzed by one-way ANOVA followed by Student's t test.

Results

Lack of Effect of Finasteride on Seizure Susceptibility.

To confirm that finasteride treatment as in the pseudopregnancy model of catamenial epilepsy does not itself alter the convulsant activity of PTZ, dose-response relationships for PTZ (30–80 mg/kg s.c.) induction of clonic seizures were determined in naive control rats 24 h after i.p. injection of vehicle or 100 mg/kg finasteride. The PTZ CD50 values in the vehicle and finasteride-pretreated groups were 55 mg/kg (95% CL, 45–67;n = 45) and 57 mg/kg (95% CL, 46–69;n = 36), indicating that finasteride does not affect seizure susceptibility.

Anticonvulsant Activity of Ganaxolone after Neurosteroid Withdrawal.

In naive female control rats, ganaxolone (0.625–15 mg/kg s.c.) protected against PTZ-induced seizures in a dose-dependent fashion (Fig. 1). Ganaxolone also protected against PTZ-induced seizures in pseudopregnant control rats and in rats that had been withdrawn from neurosteroid by finasteride treatment. In neurosteroid-withdrawn rats, the dose-response curve for anticonvulsant activity of ganaxolone was significantly (P < .05) shifted in a parallel fashion to the left from that of control rats. A marginal enhancement in the potency of ganaxolone was observed in pseudopregnant animals at dose above 1.25 mg/kg. The ED50 values derived from these data are given in Table 1. There was a significant decrease (64%) in the ED50 value of ganaxolone for seizure protection in neurosteroid-withdrawn rats compared with naive control animals, indicating an enhancement in the anticonvulsant potency of ganaxolone after neurosteroid withdrawal. To confirm that the enhanced potency of ganaxolone is not due to an action of finasteride unrelated to neurosteroid withdrawal, the anticonvulsant ED50 value of ganaxolone was determined in naive control animals that had been pretreated 24 h earlier with 100 mg/kg finasteride. The ED50 value of ganaxolone in these animals was 3.2 mg/kg (95% CL, 2.2–4.5; n = 32), which is not significantly different from the value obtained in naive control rats that had not been pretreated with finasteride (Table1).

Figure 1
Figure 1

Protection against pentylenetetrazol-induced seizures by ganaxolone in naive control female rats, finasteride-treated (neurosteroid-withdrawn) pseudopregnant rats, and pseudopregnant control rats. Animals were injected with pentylenetetrazol 15 min after the indicated dose of ganaxolone. Each point represents data from six to eight animals. The curves indicate logistic fits to the data points; ED50 values are given in Table 1.

View this table:
Table 1

Anticonvulsant activity and motor toxicity of ganaxolone in naive control, pseudopregnant control, and neurosteroid withdrawn (finasteride-treated) pseudopregnant rats

Motor Toxicity of Ganaxolone.

The motor toxicity of ganaxolone (1.25–20 mg/kg s.c.) was assessed with the rotarod test. In control animals, ganaxolone induced motor impairment at doses within the same range as those that were protective in the PTZ seizure test (Fig.2). Ganaxolone was slightly less potent in pseudopregnant control and neurosteroid-withdrawn animals, but the TD50 values derived from the dose-response data (Table 1) were not significantly different. Because the anticonvulsant ED50 value for ganaxolone in the PTZ test was reduced in the neurosteroid-withdrawal group, the protective index (TD50/ED50) was higher in neurosteroid-withdrawn than in control rats (Table 1).

Figure 2
Figure 2

Effects of ganaxolone in the accelerating rotarod test in control female rats, finasteride-treated (neurosteroid-withdrawn) pseudopregnant rats, and pseudopregnant control female rats. Animals were tested 15 min after ganaxolone administration. Each point represents data from six to eight animals.

Ganaxolone Plasma Concentrations.

Ganaxolone plasma concentrations were determined 15 min after the administration of various doses of ganaxolone (0.625–7.5 mg/kg s.c.) in control and pseudopregnant neurosteroid-withdrawn rats. Plasma ganaxolone concentrations in both control and neurosteroid-withdrawn animals increased monotonically in a dose-dependent fashion (Fig.3). Ganaxolone levels in withdrawn animals were slightly lower than those in controls with 5 and 7.5 mg/kg ganaxolone, but there were no significant differences among the data at any of the doses (P > .05). These results indicate that the enhanced anticonvulsant potency of ganaxolone in neurosteroid-withdrawn rats is not due to pharmacokinetic factors leading to increased plasma ganaxolone levels.

Figure 3
Figure 3

Plasma ganaxolone levels in control female rats and finasteride-treated (neurosteroid-withdrawn) pseudopregnant female rats. Plasma samples were taken 15 min after administration of the indicated dose of ganaxolone. Values represent the mean ± S.E. of levels in three or four animals.

Anticonvulsant Activity and Motor Toxicity of Diazepam and Valproate.

For comparison, the anticonvulsant activity and motor toxicity of diazepam and valproate were examined in control, pseudopregnant, and pseudopregnant neurosteroid-withdrawn rats. In control and pseudopregnant animals, diazepam (0.4–7.5 mg/kg i.p.) was highly effective in protecting against PTZ-induced seizures (Fig.4 and Table 1). However, in contrast to the situation with ganaxolone, where neurosteroid withdrawal was associated with enhanced anticonvulsant activity, the anticonvulsant potency of diazepam was markedly reduced in pseudopregnant animals that had undergone neurosteroid withdrawal. As shown in Fig.5, the motor toxicity of diazepam was similar in all three groups. Thus, the protective index for diazepam was reduced in animals that experienced neurosteroid withdrawal (Table1).

Figure 4
Figure 4

Protection against pentylenetetrazol-induced seizures by diazepam in control female rats, finasteride-treated (neurosteroid-withdrawn) pseudopregnant rats, and pseudopregnant control rats. Animals were injected with pentylenetetrazol 30 min after the indicated dose of diazepam. Each point represents data from six to eight animals.

Figure 5
Figure 5

Effects of ganaxolone in the accelerating rotarod test in control female rats, finasteride-treated (neurosteroid-withdrawn) pseudopregnant rats, and pseudopregnant control rats. Animals were tested 30 min after diazepam administration. Each point represents data from six to eight animals.

Valproate (100–800 mg/kg i.p.) was also effective in protecting against PTZ-induced seizures in control and pseudopregnant animals (Fig. 6 and Table 1). As with diazepam, there was a reduction in the potency of valproate after neurosteroid withdrawal, and there appeared to be a steepening of the dose-response curve. Moreover, like diazepam, neurosteroid withdrawal was not associated with a significant change in the motor toxicity of valproate (Fig. 7), so the protective index of valproate was also reduced in withdrawn animals (Table 1).

Figure 6
Figure 6

Protection against pentylenetetrazol-induced seizures by sodium valproate in control female rats, finasteride-treated (neurosteroid-withdrawn) pseudopregnant rats, and pseudopregnant control rats. Animals were injected with pentylenetetrazol 30 min after the indicated dose of sodium valproate. Each point represents data from six to eight animals.

Figure 7
Figure 7

Effects of sodium valproate in the accelerating rotarod test in control female rats, finasteride-treated (neurosteroid-withdrawn) pseudopregnant rats, and pseudopregnant control rats. Animals were tested 30 min after sodium valproate administration. Each point represents data from six to eight animals.

Discussion

The principal observation in this study is that the anticonvulsant potency of ganaxolone is enhanced in a model of perimenstrual (progesterone withdrawal type) catamenial epilepsy. There was no corresponding increase in the motor toxicity of ganaxolone. This suggests that the potentiated anticonvulsant activity of ganaxolone results from specific alterations in the brain mechanisms responsible for seizures and is not due to pharmacokinetic factors. Although the protective index of ganaxolone compares unfavorably with that of many conventional anticonvulsant agents (White et al., 1995), withdrawal was associated with increased separation between the doses producing seizure protection and motor side effects, suggesting that the drug may be better tolerated during the perimenstrual period of increased seizure frequency. However, it remains to be determined whether the enhanced potency of ganaxolone generalizes to other behavioral effects of neurosteroids, including their sedative-hypnotic, anxiolytic, and cognitive impairing effects, which may be important determinants of side effects in clinical use. Measurements of plasma ganaxolone levels revealed no increase in ganaxolone levels after withdrawal, confirming that the enhanced anticonvulsant potency was a pharmacodynamic effect and not related to pharmacokinetic factors. Interestingly, the protective activities of two other anticonvulsant agents, diazepam and valproate, were substantially reduced after neurosteroid withdrawal. Thus, neurosteroid-derived anticonvulsants such as ganaxolone may be particularly suited for the treatment of catamenial seizure exacerbations, which are often resistant to therapy with conventional anticonvulsants (Newmark and Penry, 1980).

The measurements of plasma ganaxolone levels allow us to estimate the plasma concentrations associated with seizure protection and motor toxicity. In control and neurosteroid-withdrawn animals, the threshold plasma concentrations for seizure protection were 200 to 250 and <100 ng/ml, respectively, and the estimated plasma concentrations producing 50% seizure protection were in the range of 450 to 550 and 200 to 250 ng/ml. Thus, ganaxolone protects against the PTZ-induced seizures in neurosteroid-withdrawn rats at plasma concentrations that are not anticonvulsant in control animals.

The animal model of catamenial epilepsy used in this study was designed to simulate the most common form of catamenial epilepsy in which the frequency of seizures increases in the perimenstrual period. Pseudopregnancy was induced by treatment with gonadotropins, resulting in increased ovarian production of progesterone and its 5α and 3α A-ring-reduced metabolite allopregnanolone. Diestrous plasma allopregnanolone levels in the rat are 9.3 ng/ml, and on day 12 of pseudopregnancy, the plasma levels of allopregnanolone are elevated 5-fold to 44.5 ng/ml (D. S. Reddy, H.-Y. Kim, and M. A. Rogawski, unpublished observations). The administration of the 5α-reductase inhibitor finasteride causes a fall in plasma allopregnanolone to a level of 6.4 ng/ml (24 h after dosing), which is modestly below that in the diestrous period. This fall in allopregnanolone is associated with a marked enhancement in the susceptibility to PTZ seizures (Frye and Bayon, 1998; Moran and Smith, 1998). It is attractive to speculate that a similar increase in seizure susceptibility accounts for the exacerbation of seizures in women with perimenstrual catamenial epilepsy. Although the cause of the enhanced seizure susceptibility is not well understood, there is some evidence that allopregnanolone withdrawal is associated with changes in the kinetic properties of GABAA receptors that predispose to heightened brain excitability (Smith et al., 1998). While finasteride may reduce serum allopregnanolone below control diestrous levels, Smith et al. (1998) have reported that brain levels do not fall below control levels at 24 h. Thus, the enhanced seizure susceptibility after finasteride treatment is not due to an absolute neurosteroid deficiency, and this supports the view that the heightened susceptibility is due to changes in GABAAreceptor properties. In nonpseudopregnant animals, finasteride pretreatment did not affect the convulsant activity of PTZ, indicating that it does not have proconvulsant properties in this model. This observation confirms our previous report that finasteride, at a dose much higher than used here to induce neurosteroid withdrawal, failed to affect the convulsant threshold of PTZ in mice (Kokate et al., 1999). The lack of effect of finasteride on seizure threshold in control animals suggests that basal neurosteroid levels do not have a substantial influence on seizure susceptibility. However, alterations in neurosteroid levels during the estrous cycle may affect seizure susceptibility in some models (Finn and Gee, 1994; Frye et al., 1998).

A variety of considerations indicate that the enhanced activity of ganaxolone in our model is specifically related to neurosteroid withdrawal and is not due to pseudopregnancy per se, to the effects of the hormone treatments used to induce pseudopregnancy, or to finasteride. Thus, pseudopregnant rats not undergoing withdrawal did not exhibit an overall enhanced sensitivity to ganaxolone. However, at high doses, ganaxolone appeared to have slightly greater potency in pseudopregnant control animals, although this effect did not reach statistical significance (Fig. 1). This enhanced activity may be due to the synergism between the high level of endogenous neurosteroid (present only in this group of animals) and the exogenously administered ganaxolone. In addition, finasteride pretreatment failed to alter the anticonvulsant potency of ganaxolone in control (not pseudopregnant) animals. Taken together, these observations permit the conclusion that allopregnanolone withdrawal, and not the pseudopregnant state or finasteride treatment, is responsible for the enhanced sensitivity to ganaxolone. Indeed, neuroactive steroids have previously been shown to have enhanced anticonvulsant activity after diazepam (Tsuda et al., 1997) and ethanol withdrawal (Devaud et al., 1996;1998), which, like ganaxolone, act as positive allosteric modulators of GABAA receptors. Moreover, there is a suggestion that during diestrous, when progesterone levels have fallen, allopregnanolone has increased potency as a GABAAreceptor modulator (Finn and Gee, 1993) and as an anticonvulsant against PTZ-induced seizures (Finn and Gee, 1994).

The mechanisms accounting for the enhanced anticonvulsant potency of ganaxolone after neurosteroid withdrawal were not addressed in this study. One attractive possible mechanism is that the neurosteroid sensitivity of GABAA receptors relevant to the anticonvulsant activity of ganaxolone is enhanced after neurosteroid withdrawal. Recently, however, Smith et al. (1998) have reported that hippocampal GABAA receptors show reduced sensitivity to allopregnanolone 24 h after withdrawal from allopregnanolone. Therefore, if changes in GABAAreceptor sensitivity do account for the present results, a distinct population must be involved.

In contrast to the enhanced sensitivity to ganaxolone, we observed a marked decrease in the anticonvulsant potency of diazepam and valproate. Our results are consistent with a recent study demonstrating a reduction in the sedative effects of the benzodiazepine lorazepam after progesterone withdrawal (Moran et al., 1998). This benzodiazepine insensitivity has been attributed to a specific increase in the expression of the α4 GABAA receptor subunit (Smith et al., 1998). A similar benzodiazepine insensitivity has been noted after withdrawal from barbiturates and ethanol (Buck and Harris, 1990; Roca et al., 1990). In addition, attenuated benzodiazepine sensitivity has been observed clinically in patients with premenstrual syndrome (Sundström et al., 1997a,b), a condition that may be related to catamenial epilepsy. However, it remains to be determined whether women with catamenial epilepsy have reduced sensitivity to benzodiazepines. Valproate also had markedly attenuated anticonvulsant potency after neurosteroid withdrawal. Although the basis for the anticonvulsant activity of valproate is not well understood, it may act in part through effects on GABA-mediated inhibition (Rogawski and Porter, 1990). In fact, there is evidence of cross-tolerance between benzodiazepines and valproate (Gent et al., 1986). Thus, the reduced activity of diazepam and valproate may have a similar underlying basis.

In summary, the results of this study demonstrate that there is enhanced anticonvulsant sensitivity to ganaxolone during neurosteroid withdrawal, whereas the anticonvulsant activities of diazepam and valproate are reduced. There is no corresponding enhancement of the motor toxicity of ganaxolone, so its protective index is greater after neurosteroid withdrawal than under ordinary circumstances. Thus, ganaxolone could be of use in the treatment of perimenstrual catamenial epilepsy, a condition that is often resistant to other anticonvulsant therapies.

Footnotes

  • Send reprint requests to: Michael A. Rogawski, M.D., Ph.D., National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Dr., Room 5N-250, MSC 1408, Bethesda, MD 20892-1408. E-mail: rogawski{at}nih.gov

  • Abbreviations:
    GABA
    γ-aminobutyric acid
    PTZ
    pentylenetetrazol
    CL
    confidence limits
    • Received December 21, 1999.
    • Accepted May 8, 2000.

References

  1. ↵
    1. Ansell B,
    2. Clarke E
    (1956) Epilepsy and menstruation: The role of water retention. Lancet 2:1232–1235.
    OpenUrlCrossRef
  2. ↵
    1. Azzolina B,
    2. Ellsworth K,
    3. Andersson S,
    4. Geissler W,
    5. Bull HG,
    6. Harris GS
    (1997) Inhibition of rat 5α-reductases by finasteride: Evidence for isozyme differences in the mechanism of inhibition. J Steroid Biochem Mol Biol 61:55–64.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Buck KJ,
    2. Harris RA
    (1990) Benzodiazepine agonist and inverse agonist actions on GABAA receptor-operated chloride channels. II. Chronic effects of ethanol. J Pharmacol Exp Ther 253:713–719.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Carter RB,
    2. Wood PL,
    3. Wieland S,
    4. Hawkinson JE,
    5. Belelli D,
    6. Lambert JJ,
    7. White HS,
    8. Wolf HH,
    9. Mirsadeghi S,
    10. Tahir SH,
    11. Bolger MB,
    12. Lan NC,
    13. Gee KW
    (1997) Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acidA receptor. J Pharmacol Exp Ther 280:1284–1295.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. DeLean A,
    2. Munson PJ,
    3. Rodbard D
    (1978) Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235:E97–E102.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Devaud LL,
    2. Fritschy JM,
    3. Morrow AL
    (1998) Influence of gender on chronic ethanol-induced alterations in GABAA receptors in rats. Brain Res 796:222–230.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Devaud LL,
    2. Purdy RH,
    3. Finn DA,
    4. Morrow AL
    (1996) Sensitization of γ-aminobutyric acidA receptors to neuroactive steroids in rats during ethanol withdrawal. J Pharmacol Exp Ther 278:510–517.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Duncan S,
    2. Read CL,
    3. Brodie MJ
    (1993) How common is catamenial epilepsy? Epilepsia 34:827–831.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Finn DA,
    2. Gee KW
    (1993) The influence of estrus cycle on neurosteroid potency at the γ-aminobutyric acidA receptor complex. J Pharmacol Exp Ther 265:1374–1379.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Finn DA,
    2. Gee KW
    (1994) The estrus cycle, sensitivity to convulsants and the anticonvulsant effect of a neuroactive steroid. J Pharmacol Exp Ther 271:164–170.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Frye CA,
    2. Bayon LE
    (1998) Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neurosteroid 3α,5α-THP. Neuroendocrinology 68:272–280.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Frye CA,
    2. Scalise TJ,
    3. Bayon LE
    (1998) Finasteride blocks the reduction in ictal activity produced by exogenous estrous cyclicity. J Neuroendocrinol 10:291–296.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Gasior M,
    2. Carter RB,
    3. Goldberg SR,
    4. Witkin JM
    (1997) Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J Pharmacol Exp Ther 282:543–553.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Gent JP,
    2. Bentley M,
    3. Feely M,
    4. Haigh JR
    (1986) Benzodiazepine cross-tolerance in mice extends to sodium valproate. Eur J Pharmacol 128:9–15.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Herzog AG
    (1986) Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders. Neurology 26:601–610.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Herzog AG
    (1995) Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 45:1600–1662.
    OpenUrl
  17. ↵
    1. Herzog AG,
    2. Klein P,
    3. Ransil BJ
    (1997) Three patterns of catamenial epilepsy. Epilepsia 38:1082–1088.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Jones BJ,
    2. Roberts DJ
    (1968) The quantitative measurement of motor incoordination in naive mice using an accelerating Rotarod. J Pharm Pharmacol 20:302–304.
    OpenUrlPubMed
  19. ↵
    1. Kokate TG,
    2. Banks MK,
    3. Magee T,
    4. Yamaguchi S,
    5. Rogawski MA
    (1999) Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 288:679–684.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Kokate TG,
    2. Svensson BE,
    3. Rogawski MA
    (1994) Anticonvulsant activity of neurosteroids: Correlation with γ-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther 270:1223–1229.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Laidlaw J
    (1956) Catamenial epilepsy. Lancet 271:1235–1237.
  22. ↵
    1. Monaghan EP,
    2. Navalta LA,
    3. Shum L,
    4. Ashbrook DW,
    5. Lee DA
    (1997) Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 38:1026–1031.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Moran MH,
    2. Goldberg M,
    3. Smith SS
    (1998) Progesterone withdrawal. II: Insensitivity to the sedative effects of a benzodiazepine. Brain Res 807:91–100.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Moran MH,
    2. Smith SS
    (1998) Progesterone withdrawal. I: Pro-convulsant effects. Brain Res 807:84–90.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Newmark ME,
    2. Penry JK
    (1980) Catamenial epilepsy: A review. Epilepsia 21:281–300.
    OpenUrlPubMed
  26. ↵
    1. Reddy DS,
    2. Kulkarni SK
    (2000) Development of neurosteroid-based novel psychotropic drugs. Prog Med Chem 37:135–175.
    OpenUrlPubMed
  27. ↵
    1. Roca DJ,
    2. Schiller GD,
    3. Friedman L,
    4. Rozenberg I,
    5. Gibbs TT,
    6. Farb DH
    (1990) γ-Aminobutyric acidA receptor regulation in culture: Altered allosteric interactions following prolonged exposure to benzodiazepines, barbiturates, and methylxanthines. Mol Pharmacol 37:710–719.
    OpenUrlAbstract
  28. ↵
    1. Rogawski MA,
    2. Porter RJ
    (1990) Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42:223–286.
    OpenUrlPubMed
  29. ↵
    1. Rosciszewska D,
    2. Buntner B,
    3. Guz I,
    4. Zawisza L
    (1986) Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy. J Neurol Neurosurg Psychiatry 49:47–51.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Rupprecht R,
    2. Reul JM,
    3. Trapp T,
    4. van Steensel B,
    5. Wetzel C,
    6. Damm K,
    7. Zieglgansberger W,
    8. Holsboer F
    (1993) Progesterone receptor-mediated effects of neuroactive steroids. Neuron 11:523–530.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Smith SS,
    2. Gong QH,
    3. Li X,
    4. Moran MH,
    5. Bitran D,
    6. Frye CA,
    7. Hsu FC
    (1998) Withdrawal from 3α-OH-5α-pregnan-20-one using a pseudopregnancy model alters the kinetics of hippocampal GABAA-gated current and increases the GABAA receptor α4 subunit in association with increased anxiety. J Neurosci 18:5275–5284.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Sundström I,
    2. Ashbrook D,
    3. Bäckstrom T
    (1997a) Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: A pilot study. Psychoneuroendocrinology 22:25–38.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Sundström I,
    2. Nyberg S,
    3. Bäckstrom T
    (1997b) Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 17:370–381.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Tauboll E,
    2. Lundervold A,
    3. Gjerstad L
    (1991) Temporal distribution of seizures in epilepsy. Epilepsy Res 8:153–165.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Tsuda M,
    2. Suzuki T,
    3. Misawa M
    (1997) Modulation of the decrease in the seizure threshold of pentylenetetrazole in diazepam-withdrawn mice by the neurosteroid 5α-pregnan-3α,21-diol-20-one (alloTHDOC). Addict Biol 2:455–460.
    OpenUrlCrossRef
  36. ↵
    1. Levy RH,
    2. Mattson RH,
    3. Meldrum BS
    1. White HS,
    2. Woodhead JH,
    3. Franklin MR,
    4. Swinyard EA,
    5. Wolf HA
    (1995) General principles: Experimental selection, quantification, and evaluation of antiepileptic drugs. in Antiepileptic Drugs, eds Levy RH, Mattson RH, Meldrum BS (Raven Press, New York), 4th ed. pp 99–110.
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleNEUROPHARMACOLOGY

Enhanced Anticonvulsant Activity of Ganaxolone after Neurosteroid Withdrawal in a Rat Model of Catamenial Epilepsy

Doodipala S. Reddy and Michael A. Rogawski
Journal of Pharmacology and Experimental Therapeutics September 1, 2000, 294 (3) 909-915;
Permalink:
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section